UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): June 4, 2013
KYTHERA BIOPHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
Delaware | | 001-35663 | | 03-0552903 |
| | | | |
(State or other jurisdiction
of incorporation) | | (Commission
File Number) | | (IRS Employer
Identification Number) |
27200 West Agoura Road,
Calabasas, California 91301
(Address of principal executive offices, including Zip Code)
Registrant’s telephone number, including area code: (818) 587-4500
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 5.07 Submission of Matters to a Vote of Security Holders.
On June 4, 2013, KYTHERA Biopharmaceuticals, Inc. (the “Company”) held its Annual Meeting of Stockholders (the “Annual Meeting”). At the Annual Meeting, the Company’s stockholders voted on two proposals, each of which is described in more detail Company’s definitive proxy statement on Schedule 14A and filed with the Securities and Exchange Commission on April 26, 2013. Only stockholders of record as of the close of business on April 15, 2013, the record date for the Annual Meeting, were entitled to vote at the Annual Meeting. As of the record date, 18,354,412 shares of the Company’s common stock were outstanding and entitled to vote at the Annual Meeting. The tabulation of the stockholder votes on each proposal brought before the Annual Meeting is as follows:
Proposal 1. The election of three directors to hold office until the 2016 annual meeting of stockholders or until their respective successor is elected:
Nominee | | Votes For | | Votes Withheld | | Broker
Non-Votes |
Dennis Fenton, Ph.D. | | 13,381,985 | | 9,823 | | 972,131 |
| | | | | | |
François Kress | | 13,389,856 | | 1,952 | | 972,131 |
| | | | | | |
Joseph L. Turner | | 13,390,149 | | 1,659 | | 972,131 |
| | | | | | |
Proposal 2. The ratification of the selection, by the Audit Committee of the Board of Directors, of Ernst & Young LLP as the independent registered public accounting firm of the Company for the fiscal year ending December 31, 2013:
Votes For | | Votes Against | | Abstentions | | |
14,360,246 | | 2,828 | | 865 | | |
As a routine proposal under applicable rules, no broker non-votes were recorded in connection with this proposal.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: June 6, 2013 | | KYTHERA BIOPHARMACEUTICALS, INC. |
| | |
| | By: | |
| | | /s/ Keith R. Leonard, Jr. |
| | | |
| | | Keith R. Leonard, Jr. |
| | | |
| | | President and Chief Executive Officer |
